Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Sintx Technologies, Inc. SINT

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.0M
▼ 64.7% YoY
$-10.4M
$-8.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

SINTX Technologies is an advanced ceramics company formed in December 1996 that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX provides biomedical solutions for medical devices specializing in silicon nitride (Si₃N₄) for musculoskeletal and antipathogenic applications. We also manufacture parts made from silicon nitride for customers in the electrical, aerospace and other industrial sectors. More recently, in October 2025, SINTX received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SiNAPTIC® Foot & Ankle Osteotomy Wedge System, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the United States. We presently manufacture advanced ceramic powders and components in our manufacturing facilities based in Salt Lake City, Utah.

Written from the business description in Sintx Technologies, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 20 March 2026. Every sentence was checked against that document before publication.

Growth

USD 1.0M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.0 · Net income -10.4
10M20M-15M-30M
20132016201920222025
Compound annual growth
−13.3%
+11.4%
−25.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +11.4% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−1018 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -1053.1% · Net -1018.1%
-500%-1000%-1500%
201320192025
ROE
FY2025 · ROE -303.8%
-100%-200%-300%
201320192025
Three returns, three denominators.
Gross margin45.3%
Operating margin-1053.1%
Net margin-1018.1%
EBITDAUSD -10.4M

Each USD of equity lost 304 cents this year.

Cash & shareholders

USD 0.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -8.8
-10M-20M
201320192025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks -4.2
-2M-3M
20152025

Total assetsUSD 9.5M
EquityUSD 2.9M
CashUSD 4.1M
Gross debtUSD 7,000.00
Net debtUSD -4.1M
Current ratio1.51×

The company holds more cash than debt.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SINT, 13-year financial record
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B◌◌◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−6.16−15.19−624.47−60.81−39.91−1.08−5.69−76.73−3.13−13.63−66.05−39.93−15.52
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————
ROE %−303.8−174.1−114.1−105.1−43.3−45.3−70.5−125.0−111.9−115.5−225.2——
Shares out B0.000.000.000.000.000.020.000.020.000.000.010.030.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 65 reconciliationsAUDITED

Reconciled in 13 of the 13 fiscal years we could check. 12 checks were skipped: the balance sheet is not tagged before 2013. Six checks were skipped: EPS is not tagged before 2013. Six checks were skipped: revenue is not tagged before 2013.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image